April 26, 2018

Neurimmune appoints Fabian Buller as Chief Business Officer

Schlieren / Zurich, Switzerland – April 26, 2018 – Neurimmune, a global leader in the discovery and development of human-derived monoclonal antibodies, today announced that it has appointed Dr. Fabian Buller to the newly created position Chief Business Officer. As an experienced biotech executive, Dr. Buller joins Neurimmune’s executive team and brings 8 years of professional experience with biotech and pharma companies.

“Neurimmune develops novel treatments for human diseases with high unmet medical needs. Our pipeline comprises high-potential drug candidates at both clinical and advanced preclinical development stages, including molecules that are developed in collaboration with leading pharmaceutical companies”, said Roger Nitsch, President & CEO of Neurimmune. “Following our recent raise of $150 million, we are pleased that Dr. Buller joins our company to further drive our growth strategy. Dr. Buller has an impressive track record in business development and licensing transactions. He will play a key role in realizing opportunities that will allow us to bring novel therapeutics to patients.”

Prior to joining Neurimmune, Dr. Buller served as Director New Ventures at Johnson & Johnson Innovation as well as Director Business Development of Covagen AG. He was instrumental in securing a number of major Biotech-Pharma deals including the sale of Covagen to J&J. Dr. Buller holds a PhD degree from the Institute of Chemistry and Applied Biosciences at ETH Zurich.

About Neurimmune

Neurimmune is a biopharmaceutical company dedicated to the development of human-derived therapeutic antibodies for the treatment and prevention of human diseases with a high unmet medical need. Established in 2006, Neurimmune has rapidly grown into a leader in the field of recombinant human monoclonal antibody therapeutics. Neurimmune’s pipeline comprises high-potential drug candidates at both clinical and advanced preclinical development stages. Aducanumab, an investigational treatment for Alzheimer’s disease, partnered with Biogen, is currently in phase 3 clinical trials. Rights in antibodies BIIB054 for Parkinson’s disease and BIIB076 for Alzheimer’s disease were acquired by Biogen. In 2016, Neurimmune partnered with TVM and Eli Lilly’s Chorus unit to advance an antibody for the treatment of amyotrophic lateral sclerosis. In 2017, Neurimmune entered into a collaboration with Ono Pharmaceutical in Japan. Neurimmune’s pipeline includes human antibody programs for cardiomyopathy, type-2 diabetes and progressive multifocal leukoencephalopathy, with potential therapies in advanced preclinical stages.